Akash Tewari analyst at Jefferies reiterates coverage on Exelixis (EXEL) stock in the Healthcare sector with a Buy rating. TipRanks.com has Tewari rated as a 4.4 star analyst with a 52% return on investment and a 15.9% success rate. Tewari has set a price target of $ 28.
TipRanks.com reports that Exelixis stock currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target for EXEL's stock is $30.40. The target pricing ranges from a high forecast of $35.00 down to a low forecast of $28.00. Exelixis (EXEL)’s stock last closing price was $21.33 which would put the average price target at 45.34% upside.
In addition, TradingView issued a Strong Buy rating for EXEL's stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on EXEL stock.
Click here for the full story on EXEL stock >>
TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
This article was pulled from healthtechmovers.com as they are an authority in the HealthTech Stock Sector. HealthTechMovers.com keeps investors informed of trending healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more.
DelrayResearch.com is also looking into these tickers DAWN, COGT, RMD, BSX, RACE, RTX.
Click here to join thousands of investors who have already signed up for a free subscription to consumer staples stocks newsletter PoliticsAndMyPortfolio.com.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.